In individuals with advanced -cell dysfunction, supplementing insulin therapy with pramlintide, the first and currently only approved injectable short-acting selective analog of amylin, has demonstrated efficacy in enhancing both postprandial and overall glycemic control in both type 2 diabetes (T2D) and type 1 diabetes (T1D) without increasing the risk of hypoglycemia or weight gain
Comprehensive tests range to ensure compliant and reliable drugdevice combination, leveraging know-how on standard deliverables including robustness study, device performances, pre-conditioning
That extra receptor target may matter, but it does not prove one is safer or better for any individual
Nature , 611 (7935), 365373
Expert Opinions and Ongoing Studies Experts in oncology and endocrinology have mixed opinions about the potential impact of semaglutide on breast cancer recurrence